Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company also provides Lirilumab (IPH2102/BMS-986015), a human monoclonal antibody that blocks the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH4301, an anti-MICA/B therapeutic antibody to treat oncology. The company has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi. Innate Pharma S.A. has a clinical trial collaboration with MedImmune. The company was founded in 1999 and is based in Marseille, France.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IPHYF
Previous SymbolNASDAQ:IPHYF
CUSIPN/A
Phone33-04-30-30-30-30
Debt
Debt-to-Equity RatioN/A
Current Ratio1.82
Quick RatioN/A
Price-To-Earnings
Trailing P/E Ratio-8.91
Forward P/E Ratio-20.45
P/E GrowthN/A
Sales & Book Value
Annual Sales$49.74 million
Price / Sales10.42
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.80 per share
Price / Book5.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees188
Outstanding Shares57,600,000
Market Cap$518.40 million
OptionableNot Optionable
Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions
What is Innate Pharma's stock symbol?
Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF."
What is the consensus analysts' recommendation for Innate Pharma?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innate Pharma.
Has Innate Pharma been receiving favorable news coverage?
Media headlines about IPHYF stock have trended positive on Wednesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Innate Pharma earned a news impact score of 2.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
Who are some of Innate Pharma's key competitors?
Some companies that are related to Innate Pharma include Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Endocyte (ECYT), AnaptysBio (ANAB), Supernus Pharmaceuticals (SUPN), Pacira Pharmaceuticals (PCRX), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Prestige Consumer Healthcare (PBH), Opko Health (OPK), Zogenix (ZGNX), Innoviva (INVA), Madrigal Pharmaceuticals (MDGL), Mallinckrodt (MNK) and Reata Pharmaceuticals (RETA).
Who are Innate Pharma's key executives?
Innate Pharma's management team includes the folowing people:
- Dr. Hervé Brailly, Co-Founder & Chairman of Supervisory Board (Age 57)
- Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 60)
- Mr. Yannis Morel, Exec. VP-Products Portfolio Strategy & Bus. Devel. & Member of Exec. Board (Age 45)
- Dr. François Romagné Ph.D., Co Founder and Member of the Scientific Advisory Board (Age 54)
- Ms. Laure-Hélène Mercier, Exec. VP & CFO (Age 40)
How do I buy shares of Innate Pharma?
Shares of IPHYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innate Pharma's stock price today?
One share of IPHYF stock can currently be purchased for approximately $9.00.
How big of a company is Innate Pharma?
Innate Pharma has a market capitalization of $518.40 million and generates $49.74 million in revenue each year. The company earns $-54,680,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Innate Pharma employs 188 workers across the globe.
What is Innate Pharma's official website?
How can I contact Innate Pharma?
Innate Pharma's mailing address is 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-04-30-30-30-30 or via email at [email protected]
MarketBeat Community Rating for Innate Pharma (OTCMKTS IPHYF)
MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe IPHYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPHYF will underperform the S&P 500 over the long term. You may vote once every thirty days.
